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Limited antiviral compounds are available for the control of influenza, and the emergence of resistant variants would further
narrow the options for defense. The H275Y neuraminidase (NA) mutation, which confers resistance to oseltamivir carboxylate,
has been identified among the seasonal H1N1 and 2009 pandemic influenza viruses; however, those H275Y resistant variants
demonstrated distinct epidemiological outcomes in humans. Specifically, dominance of the H275Y variant over the oseltamivir-
sensitive viruses was only reported for a seasonal H1N1 variant during 2008-2009. Here, we systematically analyze the effect of
the H275Y NAmutation on viral fitness and transmissibility of A(H1N1)pdm09 and seasonal H1N1 influenza viruses. The NA
genes from A(H1N1)pdm09 A/California/04/09 (CA04), seasonal H1N1 A/New Caledonia/20/1999 (NewCal), and A/Brisbane/59/
2007 (Brisbane) were individually introduced into the genetic background of CA04. The H275Ymutation led to reduced NA en-
zyme activity, an increasedKm for 3=-sialylactose or 6=-sialylactose, and decreased infectivity in mucin-secreting human airway
epithelial cells compared to the oseltamivir-sensitivewild-type counterparts. Attenuated pathogenicity in bothRG-CA04NA-H275Y and
RG-CA04BrisbaneNA-H275Y viruseswas observed in ferrets compared toRG-CA04 virus, although the transmissibilitywas
minimally affected. In parallel experiments using recombinant Brisbane viruses differing by hemagglutinin andNA, comparable
direct contact and respiratory droplet transmissibilitieswere observed amongRG-NewCalHA,NA, RG-NewCalHA,NA-H275Y, RG-
BrisbaneHA,NA-H275Y, andRG-NewCalHABrisbaneNA-H275Y viruses.Our results demonstrate that, despite theH275Ymutation lead-
ing to aminor reduction in viral fitness, the transmission potentials of three different antigenic strains carrying thismutationwere
comparable in the naïve ferretmodel.
Effective antiviral drugs provide immediate control during in-fluenza epidemics or pandemics. Neuraminidase (NA) inhib-
itors are recommended by WHO for the pharmacological man-
agement of the 2009 pandemic H1N1 viruses [A(H1N1)pdm09],
which carry the S31Nmutation in the M2 protein that are known
to confer resistance to adamantanes (ion channel blockers for in-
fluenza A viruses) (3). A total of 350 million treatment courses of
oseltamivir were distributed to countries worldwide for pandemic
preparedness between 2004 and December 2009 (56). Emergence
of resistant variants has been a concern with increased NA inhib-
itor usage during the H1N1 pandemic, especially if such variants
may spread efficiently among humans. Structure-based-designed
NA inhibitors target the enzyme site (66) to block the NA activity
that hydrolyzes the-ketosidic linkage between sialic acid and the
adjacent oligosaccharide. Such activity is important for establish-
ing infections (44) and for the release of viral progeny (1). NA
mutations within the enzyme site that confer resistance to NA
inhibitors would also reduce NA enzyme activity and thereby
compromise viral fitness (19). As different NAmutations result in
different levels of NA functional loss, NA inhibitor-resistant vari-
ants have been shown to differ in their fitness in vitro and in vivo
(27, 71). The fitness of the NA inhibitor-resistant variants can also
be confounded by the genetic composition of the virus, including
the hemagglutinin (HA) that binds to sialic acid-containing re-
ceptors and possesses a counteracting activity to that of NA
(19, 45).
The H275Y NA mutation (using N1 numbering) is the most
commonly reported mutation arising from oseltamivir selection
pressure within the N1 subtype. The mutation was first isolated
from 2 out of 54 human subjects post-oseltamivir treatment ex-
perimentally infectedwith seasonalH1N1 influenza virus (A/Tex-
as/36/91) (20). The H275Y mutation has also been detected in
H5N1 patients after oseltamivir treatment (10, 41). Surveillance
monitoring of influenza virus susceptibility to NA inhibitors
showed limited detection rates for this mutation among the N1
subtype prior to October 2007 (14, 49, 61, 64), but since then, a
globally spreading H275Y variant has emerged (11, 31, 40, 67),
leading to the dominance of an oseltamivir-resistant variant over
the sensitiveH1N1 strains. Epidemiological studies could not pro-
vide evidence to link this finding to oseltamivir usage, suggesting
that the transmissibility of the H275Y variant was at least compa-
rable to that of the circulating oseltamivir-sensitive strains (11, 26,
47). The sudden increase of the H1N1 oseltamivir-resistant vi-
ruses occurred concurrently with amajor change ofHA antigenic-
ity, specifically, the change from A/New Caledonia/20/1999-like
virus (NewCal; 2000/2001 to 2006/2007) to A/Solomon Island/3/
2006-like virus (2007/2008) and A/Brisbane/59/2007-like virus
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(Brisbane; 2008/2009). In addition to the change inHA antigenic-
ity, Sandbulte et al. recently reported a major change in NA anti-
genicity that was associated with the emergence of the Brisbane-
like virus (58). Studies have shown that the presence of secondary
mutations (4) or epistatic mutations (39) within NA may restore
the NA function upon acquisition of the H275Ymutation. Specif-
ically, the V234M and R222Q amino acid changes have been
shown to increase surface NA expression while accommodating
the H275Y NA mutation (4). Furthermore, mutations occurring
in the HA have been reported to promote the replication of sea-
sonal H1N1 viruses with the H275Y NA mutation (16). Collec-
tively, these studies indicate that the fitness outcome of viruses
carrying the H275Y mutation may be varied across antigenetic
strains, and therefore the emergence of new variants merits inde-
pendent investigations.
The A(H1N1)pdm09 virus, which emerged through genetic
reassortment, contains gene segments derived from human,
swine, and avian origins (15, 62), with the HA from the classical
Swine influenza virus (descendant of the 1918 pandemic virus)
and the NA from the Eurasian swine influenza virus (which orig-
inated in an avian reservoir) (59).While an increased usage of NA
inhibitors was expected during the pandemic period, the detec-
tion rate of the H275Y NA mutation among A(H1N1)pdm09 vi-
ruses was reported as only 2% in the general population (6, 7,
46, 68). A case-controlled study identified immunosuppression as
the major risk factor associated with detection of an oseltamivir-
resistant H275Y variant among hospitalized patients (6). The
transmission of the A(H1N1)pdm09 variant carrying the H275Y
NA mutation was found to be limited (9, 18, 42, 50), although
more recent studies have suggested the presence of community
transmission of oseltamivir-resistant H275Y variants in the
United States andAustralia during 2010-2011 (32, 63). The fitness
of clinically derived or recombinant A(H1N1)pdm09H275Y vari-
ants compared to their respective wild-type counterparts has been
evaluated using in vitro and animal models (5, 13, 23, 37, 48, 52,
60). The majority of these reports found that A(H1N1)pdm09
virus carrying the H275Y mutation had comparable replication
efficiency and transmissibility as that of their wild-type counter-
parts (23, 37, 48, 60), while some investigators detected a slightly
compromised viral fitness (5, 13, 24). Overall, there was little cor-
relation between the epidemiological data and the laboratory-
based in vitro or in vivo experimental findings, and there is a need
to reevaluate the role of theH275YNAmutation in viral fitness by
using selectively different virus strains to serve as control groups.
To achieve a comprehensive understanding of the various de-
grees of NA functional loss that have been implicated by studies of
the H275Y NA mutation, here we have adopted a systematic ap-
proach by generating three pairs of recombinant H1N1 viruses
that differ in their NA genes. The first pair is A(H1N1)pdm09
A/California/04/09 (CA04) viruses with orwithout theH275YNA
mutation. Two other pairs of oseltamivir-sensitive (wild-type)
and resistant recombinant CA04 viruses were generated for com-
parison, with their NA gene derived from the NewCal and Bris-
bane human seasonal H1N1 influenza virus strains known to pos-
sess different transmissibilities in human populations based on
epidemiological data.While previous studies focused primarily on
the A(H1N1)pdm09 viruses alone, we have included two previous
human seasonal H1N1 viruses into the study design. This ap-
proach allowed us to directly compare the effect of the H275YNA
mutation in three different NA backgrounds. The NA enzyme
properties were characterized, and the viral replication efficiencies
in conventional cell lines and in differentiated human normal
bronchial epithelial (NHBE) cells were evaluated. Lastly, the
transmissibilities of the CA04 recombinant viruses via direct con-
tact or respiratory droplet routes were further compared to those
of the seasonal NewCal and Brisbane viruses. This study provides
the first in vitro and in vivo comparison of the effect of the H275Y
mutation across three antigenic strains exhibiting different epide-
miological outcomes.
MATERIALS AND METHODS
Compounds. NA inhibitors oseltamivir carboxylate [GS4071; 4-N-
acetyl-5-amino-3-(1-ethylpropoxy)-1-cyclohexane-1 carboxylic acid]
was provided byHoffmann-La Roche (Basel, Switzerland), and zanamivir
(GG167; 4-guanidino-Neu5Ac2en) was provided by GlaxoSmithKline
(Stevenage, United Kingdom). The compounds were dissolved in sterile
DNase/RNase-free water, and 10mM aliquots were stored at20°C until
used.
Viruses and cells.A/NewCaledonia/20/99 (NewCal) andA/Brisbane/
59/07 (Brisbane) seasonal H1N1 influenza viruses were kindly provided
from IanBarr (WHOCollaboratingCentre for Reference andResearch on
Influenza, Australia); the A(H1N1)pdm09 A/California/04/09 (CA04) vi-
rus was provided by Robert G. Webster at St. Jude Children’s Research
Hospital. Madin-Darby canine kidney (MDCK) cells and human embry-
onic kidney 293T cells were obtained from the American Type Culture
Collection and were maintained in minimum essential medium (MEM)
with 10% fetal calf serum (FCS) and Opti-MEM (Invitrogen) supple-
mented with 5% FCS, respectively. MDCK-SIAT1 cells, which overex-
press human -2,6-sialyltransferase, were kindly provided by Mikhail N.
Matrosovich (Philipps University, Marburg, Germany) and were main-
tained as previously described (43). Differentiated NHBE cells derived
from human donors were generated as described previously (8). Briefly,
NHBE cells (Lonza) were expanded in tissue culture flasks no more than
three times before seeding onto human collagen IV-coated transwell in-
serts in 24-well plates to allow differentiation in an air-liquid interface for
at least 28 days in an incubator (5% CO2, 37°C) with BEBM medium
(Lonza) supplemented with retinoic acid as previously described (8). The
BEBM medium from the basolateral compartment was changed every
other day. Human bronchial epithelial cells (HBEC) were isolated from
patients who had undergone an operation at QueenMaryHospital, Hong
Kong; HBECwere isolated as described previously (17) and differentiated
under the same conditions as NHBE cells.
Generation of recombinant viruses. The full genome of CA04 and
Brisbane viruses as well as the HA and NA genes of NewCal virus were
amplified by one-step reverse transcription-PCR (RT-PCR; Qiagen) and
cloned into the pHW2000 plasmid as described previously (28). The
H275Y mutation was introduced into the plasmid carrying the NA gene
for all three viruses by site-directed mutagenesis (Agilent Technologies).
Recombinant viruses in the CA04 genetic background were generated by
transfecting human embryonic kidney 293T cells (TransIT-LT1; Mirus)
with eight plasmids. Cocultured MDCK and 293T cells were used to res-
cue the Brisbane andNewCal viruses due to low viral yields when we used
293T cells alone. The rescued viruses were then propagated inMDCKcells
for two or three passages at a multiplicity of infection (MOI) of 0.001
PFU/cell to prepare stocks. The HA and NA of the recombinant viruses
were verified.
Infectivity and replication kinetics.The 50% tissue culture infectious
dose (TCID50) was determined by incubating serial half-log dilutions of
virus in MDCK cells at 37°C for 72 h. A hemagglutination assay was
performed to determine the endpoint of infection, and the TCID50 was
calculated by the Reed-Muench method (57). A plaque assay was per-
formed by incubating serial dilutions of virus in confluent MDCK cells
seeded onto 6-well plates. After 1 h of incubation at 37°C, inocula were
removed and overlaid with infection medium (MEM with 0.3% bovine
serum albumin) containing 0.4% agarose. Plaques were visualized after
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incubation at 37°C for 3 days by overnight fixationwith 4% formaldehyde
in phosphate-buffered saline (PBS) followed by staining with 0.2% crystal
violet. Replication kinetics in MDCK or MDCK-SIAT1 cells was deter-
mined in triplicate wells at an MOI of 0.001 PFU/cell. After incubation,
the cells were washed and overlaid with infection medium. Supernatants
were collected at 8, 12, 24, 36, 48, and 60 h postinfection and stored at
80°C prior to virus titration. Replication kinetics in differentiated
NHBE andHBECwas determined at anMOI of 0.01 PFU/cell. To test the
potential effect of mucin at the initial stage of infection, NHBE cells were
divided into two groups, either with or without extensive PBS washings
prior to infection. Cells were infected via the apical side with 200 l of
diluted virus. After 1 h of incubation at 37°C, viral inoculum was re-
moved; both apical and basolateral surfaces of the transwell were washed
oncewith PBS before replenishmentwith freshmediumand incubation at
37°C. Virus was collected at 24, 48, 72, and 96 h postinfection by adding
200l medium onto the apical surface followed by equilibration for 15 to
20 min at 37°C, samples were stored at80°C for later titration.
Competitive growthofRG-CA04 andRG-CA04NA-H275Y indifferen-
tiatedNHBE and inMDCK-SIAT1 cells.RG-CA04 and itsmutant coun-
terpart RG-CA04NA-H275Y were mixed into four different ratios to infect
prewashed differentiated NHBE cells in duplicate transwells at anMOI of
0.01 PFU/cell. Total RNA was extracted from the inoculum (0 h postin-
fection) and viruses were collected from differentiated NHBE cells at 24,
48, and 72 h postinfection (RNeasy; Qiagen). A 475-bp PCR product was
amplified (One-step RT-PCR; Qiagen) using specific primers (forward,
5=-AGAACTCAAGAGTCTGAATGTG-3=; reverse, 5=-TCCCAGTCCAT
CCGTTCG-3=). The RT-PCR product was cloned into the pCR4-TOPO
vector (Invitrogen). PlasmidDNAwas isolated (Miniprep; Qiagen), and a
total of 20 to 40 clones were sequenced using the T3 primer, covering the
nucleotide encoding residue 275.
To test the inhibitory effects of oseltamivir in a coinfection environ-
ment, competitive growth was repeated in the presence or absence of
oseltamivir carboxylate by using MDCK-SIAT1 cells at an MOI of 0.001
PFU/cell. Sensitivity of RG-CA04 virus to oseltamivir carboxylate was
predetermined in MDCK-SIAT1 by using serial 3.16-fold dilutions of
oseltamivir carboxylate (the final concentration ranged from 0 to 100M
in triplicate samples). The half-maximal effective concentration (EC50)
was determined by plotting virus titer as a function of compound concen-
tration, followed by variable-slope dose-response curve fitting using
GraphPad Prism software. We performed the competition assay in
MDCK-SIAT1 cells under two conditions: in the absence or presence of
0.2 M oseltamivir carboxylate, which is approximately at the EC40, ac-
cording to the dose-response curve for the RG-CA04 virus. Prior to infec-
tion, MDCK-SIAT1 cells were preincubated with medium or with me-
dium containing 0.2Moseltamivir carboxylate for 1 h at 37°C. After 1 h,
cells were infected using RG-CA04 and RG-CA04NA-H275Y viruses that
were mixed into five different ratios at an MOI of 0.001 PFU/cell. Total
RNA was extracted from the inoculum (0 h postinfection) and from vi-
ruses collected at 24 and 48 h postinfection. TOPO clonal sequencing was
repeated using the same methods described above.
NA inhibition assay andNAkinetics.NA inhibitionwas assayedwith
viruses standardized to an equivalent NA enzyme activity. Viruses were
first incubated with oseltamivir carboxylate or zanamivir at concentra-
tions of 0 to 100 M at 37°C for 30 min, after which the mixtures were
further incubated with the fluorogenic substrate 2=-(4-methylumbellifer-
ryl)--D-N-acetylneuraminic acid (MUNANA) at a final concentration of
167 M (22, 53) at 37°C for 30 min. The reaction was stopped by adding
150 l stop solution (0.014 M NaCl, 0.1 M glycine in 25% ethanol; pH
10.7). The half-maximal inhibitory concentration (IC50) for each virus
was determined by plotting fluorescence as a function of compound con-
centration, followed by variable-slope dose-response curve fitting using
GraphPad Prism software. NA kinetics with MUNANA were determined
at final concentrations of 0 to 600 M at 37°C in a total volume of 50 l
with viruses diluted to approximately 5,000 PFU/ml. The fluorescence of
the released 4-methylumbelliferonewasmeasured every 68 s for 68min by
using FLUOstar Optima (BMG Labtech), with excitation and emission
wavelengths of 355 and 460 nm, respectively. NA kinetics using sialosides
3=-sialyllactose (3=SL) and 6=-sialyllactose (6=SL) as the substrates (Car-
bosynth, United Kingdom) were determined in a coupled enzyme assay.
Viruses (standardized to approximately 1.74  106 PFU/ml) were incu-
bated with 3=SL (final concentration, 0 to 4,500 M) or 6=SL (final con-
centration, 0 to 7,500 M) at pH 6.0 with 0.2 M phosphate buffer, excess
galactose oxidase (Sigma-Aldrich), horseradish peroxidase (Invitrogen),
and Amplex UltraRed reagent (Invitrogen). The reaction was conducted
at 37°C, and the fluorogenic product was measured every 5 min for 4 to 6
h using FLUOstar Optima (BMG Labtech), with excitation and emission
wavelengths of 530 and 590 nm, respectively. The enzyme kinetics data
were fitted to the Michaelis-Menten equation by using nonlinear regres-
sion (GraphPad Prism) to determine the Michaelis constant (Km) and
maximum velocity (Vmax) of substrate conversion.
Transmission experiments in ferrets. Transmissibility was tested in
4- to 6-month-old male ferrets obtained from Southland (New Zealand)
or Sangosho (China). All studies were conducted in a biosafety level 3
facility at the LKS Faculty of Medicine, the University of Hong Kong, in
compliance with all applicable laws and with ethics approval from the
Committee on the Use of Live Animals in Teaching and Research
(CULATR) at theUniversity ofHongKong. Ferrets used in the studywere
confirmed to be seronegative against influenza virus A NP protein by
using the ID Screen influenza virus A antibody competition enzyme-
linked immunosorbent assay kit (ID.vet) and had a hemagglutination
inhibition (HI) titer of 20 against pandemic influenza H1N1 virus (A/
CA/07/2009) and influenza B virus (B/Brisbane/60/08). Virus transmis-
sion experiments used groups of two inoculated ferrets, two naïve direct
contact ferrets, and two naïve respiratory droplet contact ferrets. Donors
were inoculated intranasally with 104 PFU of recombinant virus in 0.5 ml
medium under isoflurane anesthesia. All recombinant viruses used were
stock viruses after two passages in MDCK cells, except for RG-CA04,
whichwere passaged three times inMDCK cells. After 1 day, a naïve direct
contact ferret was placed in the same cage with each inoculated ferret, and
one naïve respiratory droplet contact ferret was placed in an adjacent
compartment of the cage, separated by a single-layered perforated divider.
To monitor virus shedding, nasal washes were collected from all ferrets
every other day for 14 days and titrated inMDCK cells. The area under the
curve (AUC) was calculated for each ferret as an approximation of the
cumulative amount of virus shed in the nasal washes over time by using
GraphPad Prism software. Ferret body temperatures and clinical signs
were monitored daily, and weights were recorded every other day. Naïve
respiratory droplet contact ferrets were handled before naïve direct con-
tact ferrets, and inoculated ferrets were handled last; hands and equip-
ment were disinfected before and after handling each ferret. Separate
gloves and tools were used for respiratory droplet contact ferrets.
RESULTS
Generation and characterization of A(H1N1)pdm09 H1N1 re-
combinant viruses encoding different NA genes. Three pairs of
recombinant CA04 viruses that contain NA genes from three se-
lected strains were generated, with each pair differing by the
H275Y NA mutation alone: RG-CA04, RG-CA04NA-H275Y, RG-
CA04 BrisbaneNA, RG-CA04 BrisbaneNA-H275Y, RG-CA04
NewCalNA, and RG-CA04  NewCalNA-H275Y. Recombinant vi-
ruses were generated via the eight-plasmid system in 293T cells as
described previously (28); virus stocks were prepared in MDCK
cells after two to three passages at an MOI of 0.001 PFU/cell. The
susceptibilities of the recombinant viruses to zanamivir and osel-
tamivir carboxylate were determined in enzyme-basedNA inhibi-
tion assays. We observed that the H275Y NA mutation led to an
over-1,000-fold increase in oseltamivir carboxylate IC50s, with
RG-CA04 BrisbaneNA-H275Y exhibiting the greatest with respect
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to its wild-type counterpart. All viruses remained sensitive toward
zanamivir (Table 1).
All recombinant viruses grew to comparable titers, suggesting
that theH275YNAmutationdidnot significantly affect thegrowthof
the virus in MDCK cells (Table 1). Furthermore, the comparable
growth between RG-CA04 and RG-CA04  BrisbaneNA or RG-
CA04 NewCalNA suggested that the HA/NA balance was not sig-
nificantly impairedwhenwe used these particularHA/NA combina-
tions.
The HAs and NAs of the stock recombinant viruses were se-
quenced to ensure their identities to the field strains; the intro-
duced H275Y NA mutation was confirmed to be maintained in
the recombinant viruses after two to three passages in MDCK
cells. Heterogeneous plaques were noticed with increased passage
of the recombinant viruses in MDCK cells. To explore whether
these heterogeneous plaque phenotypes were related to possible
mutations occurring inHA andNA gene sequences, the RG-CA04
and RG-CA04NA-H275Y viruses were subjected to three rounds of
plaque purification in triplicates. The clinically derived isolate
A/California/04/2009, which was grown in MDCK for five pas-
sages, also exhibited heterogeneous plaque morphology and was
included for analysis. Viral RNA was extracted from the third
round of plaque expansion, and the HA and NA genes were am-
plified using one-step RT-PCR and analyzed by Sanger sequenc-
ing. After three rounds of plaque isolation and expansion in
MDCK cells, 8 of the 18 viruses did not retain homogeneity in
plaque size (Table 2). Assessment of the 10 homogeneous pheno-
types showed amino acid changes in the HA or NA, although we
did not observe any common mutation that could be associated
with the observed large or small plaque morphology for the re-
combinant RG-CA04 or RG-CA04NA-H275Y viruses (Table 2). In
contrast, the G155E (H1 numbering) HA mutation was observed
TABLE 1 Growth and sensitivities of the recombinant viruses to NA inhibitors
Virus Virus yielda (log10 PFU/ml)
Sensitivity to NA inhibitorb
Oseltamivir carboxylate Zanamivir
IC50 (nM) Fold change IC50 (nM) Fold change
RG-CA04 6.7 0.2 0.8 0.2 1.0 0.9 0.2 1.0
RG-CA04NA-H275Y 7.1 0.4 1,205.5 16.3* 1,506.9 1.1 0.2 1.2
RG-CA04 NewCalNA 7.3 0.4 1.7 0.2 1.0 1.3 0.3 1.0
RG-CA04 NewCalNA-H275Y 7.3 0.3 2,365.5 143.5* 1,391.5 2.5 0.5 1.9
RG-CA04 BrisbaneNA 7.3 0.4 1.1 0.2 1.0 0.9 0.2 1.0
RG-CA04 BrisbaneNA-H275Y 7.3 0.3 2,060.0 216.4* 1,872.7 1.3 0.1 1.4
a Viral titers are means standard deviations derived from 2 to 3 independent experiments.
b Viral sensitivities to NA inhibitors were determined in NA inhibition assays. The values were fit to nonlinear regression curves with the variable slope model to determine the IC50,
using GraphPad Prism. Results are means standard deviations derived from 2 to 3 independent experiments. IC50 fold changes were calculated relative to the counterpart wild-
type virus. *, P 0.05 compared to the counterpart wild-type virus.










A/California/04/2009 C5 Small-1 Medium 1.04 0.26 T197A Nil
Small-2 Small 0.83 0.21 S183P Nil
Small-3 Small 0.68 0.20 L191I Nil
Large-1 Mixed, medium-large — G155E, L191I K390R
Large-2 Large 2.81 0.46 G155E, S183P Nil
Large-3 Large 2.94 0.18 G155E, S183P Nil
RG-CA04 C2 Small-1 Small 0.89 0.20 Nil V94I
Small-2 Small 0.84 0.31 Nil Nil
Small-3 Small 0.64 0.21 Nil Nil
Large-1 Large 2.44 0.50 K153Q Nil
Large-2 Medium 1.70 0.28 D127E Nil
Large-3 Mixed, small-large — G155E Nil
RG-CA04NA-H275Y C2 Small-1 Mixed, small-large — Nil Nil
Small-2 Small 0.84 0.17 Nil Nil
Small-3 Mixed, small-large — Nil S31L
Large-1 Mixed, medium-large — F390L Nil
Large-2 Mixed, medium-large — F390L Nil
Large-3 Large 2.35 0.47 N156D Nil
a Plaque diameters (means standard deviations, in mm) were determined from 5 randomly selected plaques. —, for mixed populations, mean plaque diameters were not
determined.
b Amino acid changes identified in HA and NA of heterogeneous plaques were obtained after three rounds of plaque purification in MDCK cells. After the third round of plaque
purification, RNA was isolated for RT-PCR and sequence analysis; Nil, identical to the field strain.
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consistently from the large plaques isolated from the clinically
derived CA04 virus in all triplicates (Table 2). This HA mutation
has been previously reported for the A(H1N1)pdm09 virus as one
of the mutations contributing to increased virulence after adapta-
tion in mice (34). The S183Pmutation was detected in both small
and large plaques for the clinically derived isolate and has also
been linked with increased virulence in mice (70). Overall, we
observed heterogeneity in plaquemorphology of the recombinant
A(H1N1)pdm09 virus after passaging in MDCK cells; while spo-
radic mutations were found in HA or NA after three rounds of
plaque purification in MDCK cells, the consensus sequence re-
mained identical to the field strain.
NA enzyme kinetics revealed that the H275Y NA mutation
leads to differential NA functional loss in different NA back-
grounds.To evaluate the effect of theH275Y frameworkmutation
on NA enzyme activity, kinetics assays were performed using the
fluorogenic substrate MUNANA or 3=SL and 6=SL with standard-
ized viral doses based on the PFU. Viruses carrying the H275Y
mutation showed lower Vmax and higher Km values (except RG-
CA04NA-H275Y in catalyzing 3=SL) compared to their wild-type
counterparts (Table 3), suggesting that the H275Y mutation gen-
erally led to decreased NA activity and a reduced affinity for sub-
strates.
When we applied the fluorogenic MUNANA substrate for en-
zyme kinetics, we observed that the H275Y mutation significantly
reduced the NewCal and Brisbane NA activities by 40% (P 0.05),
while only a minor reduction (10%) was observed for CA04 NA ac-
tivity (Table 3, Vmax and Vmax ratio). In addition, the H275Y muta-
tion increased theKm forCA04,NewCal, andBrisbaneNAs(Table3).
It was noted that theKm of RG-CA04Brisbane
NAwas significantly
lower (14 M) than that of RG-CA04NewCalNA (42.3 M; P
0.05) or RG-CA04 (26.5 M). The Km for RG-CA04 Brisbane
NA-
H275Y (26.4M)wasmore comparable to that of RG-CA04New-
CalNA or RG-CA04 viruses. This observation is consistentwith a pre-
vious report by Rameix-Welti et al., who compared the enzymatic
properties of seasonal H1N1 influenza viruses (54).
A similar trendwas observedwhen applying 3=SL or 6=SL as the
substrates for enzyme kinetics; the H275Y mutation significantly
reduced NA activity only for NewCal NA (3=SL) and Brisbane NA
(3=SL and 6=SL) (P  0.05). Interestingly, the RG-CA04NA-H275Y
virus did not show a decreasedVmax compared to RG-CA04 while
catalyzing 3=SL, although an20% reduction in activity was ob-
served for 6=SL. Using 3=SL as the substrate, we observed again
that the Km values of RG-CA04  NewCal
NA and RG-CA04
closely resembled that of RG-CA04 BrisbaneNA-H275Y and were
higher than that of RG-CA04 BrisbaneNA (Table 3). Using 6=SL
as the substrate, the Km values for seasonal N1 derived fromNew-
Cal or Brisbane (2,355 and 2,108M, respectively) were observed
to be lower than that of the A(H1N1)pdm09 N1 (3,469 M),
suggesting that the NAs of seasonal H1N1 viruses were more effi-
cient in catalyzing 6=SL than that of the A(H1N1)pdm09 NA.
Overall, we observed that the H275Y mutation may have led to
decreased NA activity and consistently led to increased Km values
for NAs derived from seasonal or A(H1N1)pdm09 H1N1 influ-
enza viruses.
Replication kinetics in MDCK cells and the MDCK-SIAT1
cell line yielded comparable virus replication rates between
wild-type and corresponding H275Y mutants. To assess if the
H275Y NA mutation would compromise viral growth in vitro,
multicycle replication kinetics of the recombinant viruses were
analyzed in MDCK and MDCK-SIAT1 cells (stably transfected
with -2,6-sialyl transferase) (43) at an MOI of 0.001 PFU/cell.
Our data suggest no detectable growth advantage for RG-CA04
over RG-CA04NA-H275Y in either MDCK or MDCK-SIAT1 cells
(P 0.05) (Fig. 1). Furthermore, comparable growth was observed
between RG-CA04NewCalNA and RG-CA04NewCalNA-H275Y
viruses or between RG-CA04  BrisbaneNA and RG-CA04 
BrisbaneNA-H275Y viruses in SIAT1 cells (Fig. 1). RG-CA04 
BrisbaneNA showed a marginally higher titer at 12 h postinfec-
tion in MDCK-SIAT1 cells to other viruses, except for RG-
CA04 BrisbaneNA-H275Y. Overall, the H275Y mutation in dif-
ferent N1-derived NAs did not lead to compromised growth
efficiencies in conventional cell lines.
Recombinant viruses carrying the H275Y mutation were
compromised in establishing infection in mucin-secreting dif-
ferentiatedNHBE cells.We continued to examine the replication
efficiency of the recombinant viruses in differentiatedNHBE cells,
which were previously shown to express high levels of -2,6-
linked sialic acids, human airway trypsin-like protease, as well as
ciliated and nonciliated mucin-secreting goblet cells (8). Mucin is
known to contain high level of O-linked glycans and plays an
important role in host innate defense (25, 29, 36, 65). Collectively,
these properties may provide amore physiological relevantmodel
in assessing NA inhibitor-resistant viruses.
TABLE 3 NA enzyme kinetics with MUNANA, 3=SL, and 6=SL substrates
Virus




















RG-CA04 26.5 (8.2–44.7) 4.0 (3.3–4.6) 1.0 622.7 (428.1–817.4) 101.0 (91.5–110.5) 1.0 3,469 (458.5–6,480) 68.2 (40.0–96.6) 1.0
RG-CA04NA-H275Y 61.9 (35.4–88.5) 3.5 (3.1–3.9) 0.9 905.3 (657.1–1,154) 105.8 (96.8–115.8) 1.1 4,224 (2,176–6,272) 57.8 (43.5–72.2) 0.8
RG-CA04 NewCalNA 42.3 (25.3–59.3) 4.3 (3.8–4.7) 1.0 741.5 (434.2–1,049) 111.3 (96.5–126.1) 1.0 2,355 (1,529–3,181) 84.5 (72.2–96.9) 1.0
RG-CA04 NewCalNA-H275Y 84.5 (41.2–127.9) 2.4 (2.1–2.8)* 0.6 1,370.0 (178.5–2,561) 69.5 (45.1–93.95)* 0.6 3,987 (1,586–6,389) 57.2 (39.9–74.6) 0.7
RG-CA04 BrisbaneNA 14.0 (3.6–24.4)§ 6.8 (5.7–7.9) 1 454.2 (143.6–764.8) 152.0 (124.0–180.1) 1.0 2,108 (1,425–2,790) 105.6 (92.0–119.3) 1.0
RG-CA04 BrisbaneNA-H275Y 26.4 (13.5–39.3) 4.3 (3.8–4.8)* 0.6 698.9 (400.0–997.8) 97.5 (84.4–110.6)* 0.6 2,462 (1,646–3,278) 67.8 (58.3–77.3)* 0.6
a Standardized virus doses were used for the NA kinetics assay. The enzyme kinetics data were fit to the Michaelis-Menten equation by nonlinear regression to determine the
Michaelis constant (Km) and maximum velocity (Vmax) of substrate conversion by using GraphPad Prism. Results are means from 2 independent experiments. *, P 0.05
compared to the counterpart wild-type virus; §, P 0.05 compared to the RG-CA04 NewCalNA virus.
b The Vmax ratio of the value for the H275Y variant relative to that of its cognate wild-type NA is shown.
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To evaluate the infectivity of the recombinant viruses with or
without the H275Y mutation in differentiated NHBE cells, the
cells derived from two different donors (Lonza, Switzerland) were
subjected to extensivewashingwith PBS (cells derived fromdonor
1) or no washing (donors 1 and 2) prior to infection. Using cells
from the prewashed protocol, all three wild-type viruses (RG-
CA04, RG-CA04  NewCalNA, and RG-CA04  BrisbaneNA)
were able to establish infection in 4/4 replicates, with viral titers
peaking at approximately 72 h postinfection (Fig. 2). The recom-
binant viruses carrying the H275Y mutation, RG-CA04NA-H275Y,
RG-CA04NewCalNA-H275Y, andRG-CA04BrisbaneNA-H275Y,
successfully established infection in prewashed cells in 3/4, 3/4,
and 2/4 replicates, respectively (Fig. 2). Comparable viral titers
was observed between the replicates successfully infected by the
wild-type and the H275Y counterparts, suggesting comparable
replication kinetics once the infection was established. Among the
transwells that were not successfully infected, no detectable
plaques were found across all time points (detection limit, 10
PFU). In differentiated NHBE cells that were left unwashed in
order to maintain the mucin layer intact prior to infection, we
observed that recombinant viruses carrying the NAH275Ymuta-
tion showed a reduced ability to successfully initiate infection.
For wild-type viruses, we observed that RG-CA04, RG-CA04 
NewCalNA, and RG-CA04  BrisbaneNA could establish infection
in 4/5, 5/5, and 3/5 replicates of the unwashed differentiated NHBE
cells, respectively (Fig. 2). For the viruses carrying the H275Y NA
mutation, RG-CA04NA-H275Y, RG-CA04 NewCaledoniaNA-H275Y,
and RG-CA04 BrisbaneNA-H275Y could only establish infection in
2/5,1/5, and1/5replicatesof theunwasheddifferentiatedNHBEcells,
respectively. Due to the small sample size, a statistically significant
difference was only observed between the RG-CA04  NewCalNA
and CA04 NewCaledoniaNA-H275Y viruses (Fig. 2C) (P	 0.0476;
Fisher’s exact test). Overall, by using mucin-secreting differentiated
NHBE cells (derived from two different donors) as an alternative in
vitromodel,weobserved that recombinantCA04viruses carrying the
H275Ymutation led to a consistently reduced ability to establish in-
fection in the unwashed cells, regardless if the NA originated from
A(H1N1)pdm09 or seasonal H1N1 viruses.
Well-differentiatedHBECderived frompatients who had under-
gone lung resections were also applied to compare the infectivities of
the recombinant seasonal influenza viruses RG-Brisbane and RG-
BrisbaneNA-H275Y. In parallel, we included the infection of RG-
CA04  BrisbaneNA and RG-CA04  BrisbaneNA-H275Y viruses for
comparison.These cells havebeen characterized to exhibit properties
similar to differentiated NHBE cells (R. W. Y. Chan and M. C. W.
Chan, unpublished data) and also secrete mucin. Infection experi-
ments were performed on unwashed differentiated HBEC derived
fromonedonor. Results showed that all viruses could establish infec-
tion in HBEC: RG-Brisbane (2/2 replicates), RG-BrisbaneNA-H275Y
(3/3 replicates), RG-CA04  BrisbaneNA (2/2 replicates), and RG-
CA04  BrisbaneNA-H275Y (3/3 replicates). It is not known if the
amounts of mucin or the compositions of the mucin secreted
from differentiated NHBE and HBEC were comparable. These
results highlight the existence of donor-to-donor variability when
using primary cells.
TOPO cloning for sequencing of coinfected RG-CA04
and RG-CA04H275Y viruses in vitro. To understand if the
A(H1N1)pdm09 virus possessed a survival advantage over its
H275Y NA counterpart, RG-CA04 and RG-CA04NA-H275Y viruses
were mixed at 100:0, 71:29, 41:59, and 0:100 ratios (verified by
TOPO clonal sequencing) to coinfect the differentiated NHBE
cells, which were washed extensively with PBS prior to infection.
For eachmixture, duplicate transwells were infected using anMOI
of 0.01 PFU/cell, and viruseswere collected from the apical surface
every 24 h until peak titers were reached, at approximately 72 h
postinfection.
At ratios of 100:0 and 0:100, we observed that both the RG-
CA04 and RG-CA04NA-H275Y genotypes were stably maintained at
24, 48, and 72 h postinfection, suggesting the genetic stability of
the H275Y NA mutation. With coinfection at a ratio of 71:29
(H275:Y275), we observed that RG-CA04 became dominant
(100%) at 24 h (replicate 1) or 72 h (replicate 2) postinfection. For
cells infected using the ratio of 41:59 (H275:Y275), we observed
that RG-CA04 became dominant at 24 h (95%; replicate 1) or 72 h
(90%; replicate 2) postinfection (Fig. 3A); however, we noticed an
increase of RG-CA04NA-H275Y in replicate 1 at 72 h postinfection.
FIG 1 Replication kinetics of the recombinant CA04 viruses in MDCK and MDCK-SIAT1 cells. Multicycle replication curves were determined at an MOI of
0.001 PFU/cell inMDCKandMDCK-SIAT1 cells with triplicatedwells. Viruseswere collected at the specified time points, andmean ( standard deviation) log10
values are shown. The detection limit was 10 PFU/ml. *, P 0.05.
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Overall, our results suggest the genetic stability of the H275Ymu-
tation in A(H1N1)pdm09 virus and a slightly higher survival ad-
vantage of RG-CA04 over RG-CA04NA-H275Y virus when coin-
fected at different ratios in prewashed differentiated NHBE cells.
We extended the competition experiment between the RG-
CA04 and RG-CA04NA-H275Y in MDCK-SIAT1 cells and further
evaluated the changes of the oseltamivir-sensitive and oseltamivir-
resistant populations in the absence or presence of oseltamivir
carboxylate. Susceptibility of RG-CA04was first determined using
increasing concentration of oseltamivir carboxylate (0 to 100M)
in MDCK-SIAT1 cells. The EC50 of CA04 virus determined in
MDCK-SIAT1 cells (0.76 M, 95% confidence interval [CI], 0.28
to 2.05 M) was found slightly higher than the EC50 previously
reported in MDCK cells (0.18 M) (51). Five different ratios
(100:0, 80:20, 50:50, 30:70, and 0:100) of RG-CA04 and RG-
CA04NA-H275Y viruses were then used for the coinfection experi-
ment in the absence or presence of 0.2 M oseltamivir carboxy-
late, which approximated the EC40 forRG-CA04 inMDCK-SIAT1
cells. For cells infected in the absence of oseltamivir carboxylate, a
general trend of increasing RG-CA04 genotype over time was ob-
served (with the exception of cells infected at 80:20 and 30:70
ratios at 24 h postinfection) (Fig. 3B); however, the H275 did not
completely dominate over the Y275, even with a premixed ratio of
80:20 (H:Y) at 48 h postinfection. For cells infected in the presence
of oseltamivir carboxylate, a progressive decrease in the propor-
tion of RG-CA04 was observed across all three mixtures (80:20,
50:50, and 30:70) over time; RG-CA04 was not detectable at 48 h
postinfection for cells initially infected with 50:50 and 30:70 ratios
FIG 2 Replication efficiency of the recombinant CA04 viruses in differentiated NHBE cells. The abilities of the recombinant viruses to replicate in prewashed or
unwashed differentiated NHBE cells (derived from two donors) prior to infection were evaluated. Replication efficiencies are shown between RG-CA04 and
RG-CA04NA-H275Y (A), RG-CA04 NewCalNA and RG-CA04 NewCalNA-H275Y (B), and RG-CA04 BrisbaneNA and RG-CA04 BrisbaneNA-H275Y. Each
data point represents the titer (in log10 PFU/ml) from one transwell collected at the specified time points.Mean titer values at each time point from the transwells
with positive viral replication are denoted by horizontal lines.
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(Fig. 3B). In summary, our results suggest that RG-CA04 pos-
sesses a minor survival advantage over RG-CA04NA-H275Y in the
absence of oseltamivir carboxylate in both NHBE and MDCK-
SIAT1 cells. Coinfection with H275 and Y275 genotypes in the
presence of oseltamivir carboxylate resulted in a gradual depletion
of the oseltamivir-sensitive H275 genotype over time.
Transmissibility of the recombinant A(H1N1)pdm09 vi-
ruses in ferrets. The transmissibility of the recombinant CA04
viruses was evaluated in the ferret model. At an inoculation dose
of 104 PFU, ferrets infected with RG-CA04 virus exhibited greater
levels of weight loss (Fig. 4A) and were less active and playful
compared to the ferrets inoculated with RG-CA04NA-H275Y (Fig.
4B) or RG-CA04 BrisbaneNA-H275Y (Fig. 4C) viruses. One of the
two ferrets inoculated with RG-CA04 virus died on day 8 postin-
oculation, while all ferrets survived in the RG-CA04NA-H275Y and
RG-CA04 BrisbaneNA-H275Y groups. Transmission from inocu-
lated ferrets to naïve direct contact and respiratory droplet contact
ferrets was observed for all three recombinant CA04 viruses at day
4 postinoculation (day 3 postcontact) (Fig. 4). The AUC approx-
imating the total amount of virus shed during the course of infec-
tion was calculated for each animal; while the donor or the direct
contact ferrets infected by RG-CA04NA-H275Y consistently
showed lower AUC values, the differences were not statistically
significant, due to small sample sizes (Table 4). Overall, with a
small sample size, we observed that RG-CA04NA-H275Y or RG-
CA04  BrisbaneNA-H275Y viruses possessed attenuated patho-
genicities but retained comparable transmission efficiencies to
the RG-CA04 virus.
Transmissibility of the recombinant seasonal H1N1 viruses
in ferrets. The transmissibility of human seasonal H1N1 virus
FIG 3 Competitive replication of RG-CA04 and RG-CA04NA-H275Y in vitro. RG-CA04 and RG-CA04NA-H275Y viruses were premixed at different ratios prior to
infection of differentiated NHBE (A) or MDCK-SIAT1 (B) cells in the absence or presence of 0.2 M oseltamivir carboxylate. TOPO clonal sequencing was
performed to determine the ratio of RG-CA04 and RG-CA04NA-H275Y viruses at different times postinfection. NHBE cells in two separate transwells (replicates
1 and 2; both with no oseltamivir treatment) were washed with PBS prior to infection withmixtures of RG-CA04 and RG-CA04NA-H275Y viruses. The percentage
of the oseltamivir-sensitive H275 genotype is shown in red, while the percentage of the oseltamivir-resistant Y275 genotype is shown in pink. Numbers of clones
(n) sequenced at each time point are indicated in each panel.
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carrying the H275Y NA mutation has been previously studied in
ferrets using strains circulating prior to 2007 (A/Texas/36/91 and
A/New Caledonia/20/99) (27, 35) or after 2007 (A/Brisbane/59/
2007) (33). While the H275Y mutation was shown to reduce the
infectivity of seasonal H1N1 viruses isolated before 2007 in ferrets
(27, 35), donor ferrets successfully infected with NewCal-like vi-
rus carrying theH275Ymutationwere able to transmit the virus to
naïve direct contact ferrets (27). The transmission potentials of
the Brisbane-like viruses carrying the H275Y NA mutation were
previously evaluated using a coinfection model in ferrets; the
H275Ymutant was reported to possess comparable transmissibil-
ity, albeit being marginally outgrown by the wild-type virus (33).
Given that these studies were performed under different experi-
mental conditions, our ability to clearly compare results obtained
previously is limited. Here, we aimed to perform a side-by-side
comparison among seasonal H1N1 influenza viruses that circu-
lated prior to and after 2007 under identical experimental settings.
Since the HA and NA may confer to NA inhibitor resistance, and
a balanced activity between the two surface glycoproteins is im-
portant for viral fitness, we focused on HA and NA derived from
the NewCal and Brisbane viruses, of which the H275Y variants
have showndifferent epidemiological outcomes. Recombinant vi-
ruses with identical internal genes derived from the Brisbane virus
but differing in the surface glycoproteins were generated: RG-
BrisbaneHA,NA, RG-BrisbaneHA,NA-H275Y, RG-NewCalHA,NA, RG-
NewCalHA,NA-H275Y, RG-BrisbaneHA  NewCalNA-H275Y, and
RG-NewCalHABrisbaneNA-H275Y. These viruses replicated to com-
parable titers in MDCK cells except for RG-BrisbaneHA,NA-H275Y,
which replicated to a significantly lower titer compared to RG-
BrisbaneHA,NA at 12hpostinfection inMDCK-SIAT1cells (P0.05)
(Fig. 5). The RG-BrisbaneHANewCal NA-H275Y virus that was ob-
served to possess an additional N125Y HA mutation replicated to a
lower titer inMDCK-SIAT1 cells (data not shown).
We continued to evaluate the transmissibility of four selected
recombinant seasonal H1N1 viruses (RG-BrisbaneHA,NA-H275Y,
RG-NewCalHA,NA, RG-NewCalHA,NA-H275Y, and RG-NewCalHA 
BrisbaneNA-H275Y) in the ferret model. At the inoculation dose of 104
PFU, peak titers were detected at 2 days postinoculation from donor
ferrets inoculated with RG-BrisbaneHA,NA-H275Y, RG-NewCalHA,NA,
RG-NewCalHA,NA-H275Y, or RG-NewCalHA  BrisbaneNA-H275Y,
with titers ranging from 6.4 to 8.3 log10TCID50/ml (Fig. 6).
Transmission of all four viruses to naïve ferrets cohoused with
donor ferrets was detected at 4 days postinoculation, with peak
titers ranging from 5.7 to 7.3 log10TCID50/ml (Fig. 6). At 4
days postinoculation, transmission of RG-NewCalHA,NA and RG-
NewCalHA  BrisbaneNA-H275Y to 2/2 naïve respiratory droplet
contacts was detected, whereas for RG-NewCalHA,NA-H275Y and RG-
BrisbaneHA,NA-H275Y, only 1/2 and 0/2 naïve contacts became infected,
respectively. Transmission of RG-NewCalHA,NA-H275Y and RG-
BrisbaneHA,NA-H275Y was then detected from all naïve respiratory
droplet contacts at 6 days postinoculation (Fig. 6). By comparing the
RG-NewCalHA,NA and RG-NewCalHA,NA-H275Y viruses, we observed
that the H275Y NAmutation slightly decreased the respiratory droplet
transmissibility but not the direct contact transmissibility; however, sta-
tistical analysis couldnotbeperformeddue to the small sample size.The
transmissibilities of the RG-NewCalHA,NA and RG-NewCalHA 
BrisbaneNA-H275Yvirusesweremorecomparable.Overall,weobservedat
the inoculation dose of 104 PFU/ferret, all seasonalH1N1 viruses carry-
ingtheH275YNAmutationcouldtransmittoferretsundercohousedor
respiratory droplet contact settings.









RG-CA04 C3 6.9 2.4 8.6 5.3 4.9 1.0
RG-CA04NA-H275Y 4.9 0.8 2.9 1.9 3.8 1.1
RG-CA04 BrisbaneNA-H275Y 6.1 1.9 5.2 1.7 5.4 1.9
RG-NewCalHA,NA 9.3 0.9 7.4 2.3 8.7 0.7
RG-NewCalHA,NA-H275Y 8.2 1.0 8.4 1.2 7.6 3.1
RG-NewCalHA BrisbaneNA-H275Y 10.1 0.1 7.0 2.7 8.9 0.5
RG-BrisbaneHA,NA-H275Y 8.8 1.2 8.8 0.9 7.1 2.9
a The AUC represents total virus shedding (in log10 TCID50/ml) at 2, 4, 6, 8, 10, and 12
days postinoculation (1, 3, 5, 7, 9, and 11 days postcontact), as calculated from the nasal
washes of each ferret. Means standard deviations of results from two donors, two
direct contacts, or two respiratory droplet contact ferrets are shown. The detection limit
was 102.2 TCID50/ml.
FIG 4 Transmission of RG-CA04, RG-CA04NA-H275Y, and RG-CA04 Bris-
baneNA-275Y viruses in ferrets. The direct contact and respiratory droplet con-
tact transmissibility of RG-CA04 (A), RG-RG-CA04NA-H275Y (B), and RG-
CA04 BrisbaneNA-H275Y (C) viruses are shown. Ferret weight changes (% of
weight change compared to the weight at day 0; mean standard deviation)
are also shown. Viral titers (in log10 TCID50/ml) were obtained from the nasal
washes of individual donor ferrets (yellow), direct contacts (green), and respi-
ratory droplet contacts (blue). The detection limit was 102.2 TCID50/ml. One
donor animal inoculated with RG-CA04 virus was found dead in the cage at
day 8 postinoculation.
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DISCUSSION
The H275Y mutation that confers resistance to oseltamivir car-
boxylate has been detected from human infections of different
influenza N1 subtypes, including seasonal H1N1 (11, 20, 31, 40,
49, 61, 67), highly pathogenic H5N1 (10, 41), and more recently,
in A(H1N1)pdm09 viruses (18, 21, 30, 32, 63). Epidemiological
data suggest that the fitness and the transmission potential of re-
sistant variants carrying the H275Y NA mutation may vary be-
tween strains, with the observation of the unprecedented global
spread of the Brisbane-like seasonal H1N1 virus during the 2008-
2009 influenza season.While different in vitroor in vivomodels (5,
13, 23, 27, 33, 35, 37, 48, 52, 60) were used to evaluate the fitness of
viruses carrying theH275Ymutation, its effect on differentN1NA
cannot be directly compared. The effect of this mutation in vitro
has been previously addressed in a systematic manner by using
different seasonal H1N1 influenza viruses (2), while in the present
study we used three antigenically representative human seasonal
strains, including the pandemic 2009 virus. Our results showed
that the H275Y mutation consistently led to reduced NA enzyme
function and a decreased ability to establish infection in mucin-
secreting primary airway epithelial cells. Under coinfection con-
ditions in NHBE and MDCK-SIAT1 cells, we also observed a mi-
nor survival advantage of RG-CA04 over RG-CA04NA-H275Y in the
absence of oseltamivir carboxylate. Despite the detections of re-
duced viral competencies, both seasonal and A(H1N1)pdm09 vi-
ruses carrying the H275Ymutation were efficiently transmitted to
naïve direct contact or respiratory droplet contact ferrets under
the same experimental condition that a control swine influenza
virus could only transmit to the naïve direct contact ferrets but not
to the respiratory droplet contacts (data not shown). Our results
suggest that the H275Ymutation inH1N1 influenza virus leads to
a minor reduction in viral fitness, with its transmission potential
being minimally affected in the ferret model.
Previous studies on NA inhibitor-resistant variants have
shown that mutations within or surrounding the enzyme active
site can impose different levels of NA functional loss (27, 71, 72).
Our data are in accord with studies demonstrating that H275Y-
carrying viruses have higher Km and lower Vmax values than their
wild-type counterparts (5, 13, 52, 54, 73). When comparing the
enzyme activities among the three different NA, we observed, us-
ing MUNANA or 3=SL substrates, that the Km value of RG-
CA04  BrisbaneNA-H275Y remained within close range to RG-
CA04 and RG-CA04  NewCalNA viruses, while the Km of
RG-CA04 BrisbaneNA consistently remained the lowest among
all. Although we did not directly compare the HA binding effi-
ciency in the presence of different NA, it is hypothesized that NA
with a lowKm for sialosidesmay interferewith theHAbinding and
FIG 5 Replication kinetics of the recombinant seasonal H1N1 viruses in MDCK and MDCK-SIAT1 cells. Multicycle replication curves were determined at an
MOI of 0.001 PFU/cell in MDCK and MDCK-SIAT1 cells in triplicate wells. Viruses were collected at the specified time points, and the mean ( standard
deviation) log10 values are shown. The detection limit was 10 PFU/ml. *, P 0.05.
FIG 6 Transmission of RG-NewCalHA,NA, RG-NewCalHA,NA-H275Y, RG-
NewCalHA  BrisbaneNA-H275Y, and RG-BrisbaneHA,NA-H275Y viruses in ferrets.
The direct contact and respiratory droplet contact transmissibilities of RG-
NewCalHA,NA (A), RG-NewCalHA,NA-H275Y (B), RG-NewCalHABrisbaneNA-H275Y
(C),andRG-BrisbaneHA,NA-H275Y (D)virusesare shown.Viral titers (in log10TCID50/
ml) were obtained from the nasal washes of individual donor ferrets (yellow), direct
contacts (green), and respiratorydroplet contacts (blue).Thedetection limitwas102.2
TCID50/ml.
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may not be necessarily advantageous for a virus, especially during
the initiation of infection. This finding has been previously re-
ported in a study investigating the NA enzymatic properties of
seasonal H1N1 virus (54) and also identified the D344N substitu-
tion among H1N1 viruses circulating in 2007-2008 as the major
determinant for increased affinity to sialic acids (55). The unique-
ness of Brisbane-like NA has been described in other studies, in-
cluding the identification of secondary mutations (4) or epistatic
mutations (39) thatmay restore theNA function upon acquisition
of the H275Y NA mutation.
We observed that the Km values for NA derived from seasonal
H1N1 viruses were lower than that of the A(H1N1)pdm09 virus
when applying 6=SL substrate, suggesting the NA derived from
seasonal viruses is more efficient in catalyzing 6=SL. The adapta-
tion of the avian origin N2 NA in humans has been previously
investigated, with the observation of increased activity in catalyz-
ing 6=SL over time (38). As the A(H1N1)pdm09 virus acquired its
NA gene from the “Eurasian” swine lineage (15, 62), which orig-
inally came from avian species and has been established in swine
since the 1970s (12, 59), it is not clear if adaptation of avian origin
viruses in swine may also lead to increased NA activity for 6=SL.
The use ofmucin-secreting differentiatedNHBE cells provides
a physiologically relevant model to assess viruses with impaired
NA activity, which viruses show little or no compromised growth
in cell lines such as MDCK or MDCK-SIAT cells. Our results
suggest mucin plays a protective role in innate defense; by using
cells of the same donor, we showed that extensive PBS washings
prior to infection rendered the cells more permissive to infection.
Furthermore, we observed that recombinant viruses carrying the
H275Y NA mutation, which have reduced NA activity, were less
efficient in initiating infection than their wild-type counterparts
in the unwashedNHBE cells, which presumably had amore intact
mucin layer. It was also noted that once the infection was estab-
lished, H275Y-carrying recombinant viruses could replicate to
comparable titers as their wild-type counterparts, and this reca-
pitulates the situation observed in conventional MDCK and
MDCK-SIAT1 cell lines. Although we were not able to quantify
the amount of mucin or other contents being secreted by the cells,
these results support previous studies that influenza virus NA is
functionally important for initiating infection in human airway
epithelium (44).
We addressed the relative fitness of RG-CA04 and RG-
CA04NA-H275Y by infecting prewashed differentiated NHBE cells
and MDCK-SIAT1 cells with the two viruses mixed at different
ratios. We observed that the H275Y mutation may have slightly
reduced the survival advantage of the virus in the absence of osel-
tamivir carboxylate, albeit being genetically stable over time. A
previous study performing coinfection of recombinant
A(H1N1)pdm09 viruses carrying H275 or Y275 NA residues in
human airway epithelial cells also observed enrichment of the
H275 genotype after 72 h postinfection; however, no growth ad-
vantage was observed for either virus when the coinfection was
performed in MDCK cells (5). In addition to testing the survival
advantage of RG-CA04 and RG-CA04NA-H275Y in a competitive
mixtures assay, the influence of oseltamivir carboxylate was also
tested in MDCK-SIAT1 cells. As expected, the TOPO clonal se-
quencing showed that the proportion of the oseltamivir-sensitive
H275 genotype progressively declined over time. More impor-
tantly, our results demonstrated the viable coexistence of oselta-
mivir-sensitive and -resistant populations while under partial os-
eltamivir pressure (exposure to the EC40 for sensitive virus).
The transmission results showed a robust data set, which all
point toward the ability for H275Y-carrying viruses to transmit
efficiently to naïve ferrets either under cohousing or respiratory
droplet contact settings. It has been well established through epi-
demiological observations that the Brisbane-like viruses carrying
the H275Y mutation are easily transmissible among humans,
while only low-level transmission of the H275Y variants was re-
ported prior to 2007-2008 (14, 64). However, our data and a pre-
vious report (33) did not find a unique transmission potential for
the BrisbaneNA-H275Y virus in this animal model. In fact, we
showed that RG-NewCalHA,NA and RG-NewCalHA,NA-H275Y could
both transmit via direct contact and respiratory droplet routes,
with RG-NewCalHA,NA-H275Y showing a slight delay in respiratory
droplet transmissibility. While ferrets provide a naïve animal
model for us to evaluate the transmission potential of the influ-
enza viruses, the effect of exposure to prior circulating strains
cannot be fully addressed. Oseltamivir-resistant Y275 variants cir-
culating during the 2008-2009 season showed reduced antigenic-
ity compared to the oseltamivir-sensitive strains (69).More recent
research has also shown that the NA of Brisbane-like viruses has
undergone a major drift in antigenicity from previously circulat-
ing seasonal H1N1 viruses (58).
In conclusion, we have shown that the H275Y NA mutation
conferring oseltamivir resistance can lead to NA functional loss in
A(H1N1)pdm09 and seasonal H1N1 viruses. The reduced NA ac-
tivity may affect the ability of the viruses to establish infection in
the human airway, in the presence of mucin. However, all viruses
carrying the H275Ymutation were found to be able to transmit to
naïve direct contact and respiratory droplet contact ferrets. Our
results support the urgent need for the development of novel an-
tiviral compounds or alternative treatment options for the control
of influenza virus infections.
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